替莫唑胺配合放疗治疗原发性中枢神经系统淋巴瘤的临床观察

Clinical study of temozolomide combinated with radiotherapy for primary central nervous system lymphoma

目的:探讨替莫唑胺配合放疗对原发性中枢神经系统淋巴瘤(PCNSL)患者的治疗效果。方法:回顾性分析我院2006-06-2010-03应用替莫唑胺配合放疗治疗的33例PCNSL患者的临床资料。结果:随访1～46个月,其中达到完全缓解11例(33.3%),部分缓解3例(9.1%),有效率为42.4%。稳定病灶患者9例(27.3%),进展性病灶患者10例(30.2%),生存时间1～46个月,中位生存期26个月。结论:不良反应主要为恶心、呕吐、脱发、疲倦、肝功损害和骨髓抑制等,程度较轻。替莫唑胺同步化疗配合放疗是治疗原发性中枢神经系统淋巴瘤安全、有效的方法,值得临床推广。

OBJECTIVE：To explore the efficacy of temozolomide （TMZ） combined with radiotherapy treatment in the primary central nervous system lymphoma （PCNSL）.METHODS：The data of 33 PCNSL patients treated with temozolomide （TMZ） combinated with radiotherapy were retrospectively analyzed from June 2006 to March 2010.RESULTS：All the patients were followed up for 1-46 months.Eleven patients （33.3%） achieved complete response （CR）,and 3 （9.1%） partial response （PR）.The efficient rate was 42.4%.Stable disease was documented in 9 patients （27.3%） while progressive disease occurred in 10 patients （30.2%）.The survival time was 1-46 months.The median survival time was 26 months.CONCLUSION：TMZ combinated with radiotherapy is a safe and effective multimodality therapy for PCNSL and can be applied clinically.